Breakthrough Disease Treatment Drug Creation with Lactic Acid Bacteria Exosomes (Extracellular Vesicles; EVs). LAB Biotech Initiates Joint Research for Novel Ophthalmic Drug Discovery.
NQ Score
97/100
N1 Content Completeness
90
AI Summary (NQ-processed)
LAB Biotech starts joint research with DWTI on ophthalmic therapeutics using lactic acid bacteria EVs, aiming for breakthrough drug discovery.
AI Analysis
Frequently Asked Questions
- Q: What are Lactic Acid Bacteria EVs?
- A: Extracellular vesicles secreted by lactic acid bacteria, involved in intercellular communication, with potential for drug delivery and anti-inflammatory effects.
- Q: Why are Lactic Acid Bacteria EVs attracting attention in ophthalmology?
- A: Due to their ability to pass through the intestinal tract and BBB, and confirmed anti-inflammatory effects in some EVs, they are expected for eye drop application.
- Q: What are the roles of DWTI and LAB Biotech in this collaboration?
- A: DWTI handles clinical development and formulation design, while LAB Biotech focuses on EVs purification, library construction, and evaluation.